Icrucumab, an innovative monoclonal antibody, is now undergoing rigorous clinical evaluation for its application in multiple inflammatory diseases. Initial studies suggest a promising mechanism of function, selectively targeting the role of IL-17, a key cytokine implicated in autoimmune responses. The production path has faced certain obstacles,… Read More

Datopotamab Deruxtecan, often abbreviated as DATO, represents a notable advancement in targeted cancer treatment. This innovative Datopotamab antibody drug conjugate antibody-drug conjugate joins a monoclonal immunoglobulin specifically directed at HER2 expressing cells with the potent… Read More